Through our partnership with XORTX Therapeutics Inc., we are delighted to have placed Dr. Michael Bumby as Chief Financial Officer (CFO).
Michael brings extensive executive corporate financial leadership, demonstrated expertise in navigating US and Canadian capital market ecosystems and a proven track record in pharmaceutical sector leadership to this role.
XORTX Therapeutics Inc. (“XORTX”) is a pharmaceutical company with two clinically advanced products in development: 1) our lead, XRx-008 program for ADPKD; and 2) our secondary program in XRx-101 for acute kidney and other acute organ injury associated with Coronavirus / COVID-19 infection. In addition, XRx-225 is a pre-clinical stage program for Type 2 Diabetic Nephropathy. XORTX is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid.
At XORTX, we are dedicated to innovating and developing medications to improve the quality of life and future health of patients. The company is led by management and kidney disease experts dedicated to improving the quality of life of patients with kidney disease by slowing disease progression. We are passionate about pioneering new therapies to reduce the negative health consequences of kidney disease.
The company is a well-capitalized, publicly-traded (NASDAQ/TSX) Canadian healthcare company with head office in Calgary, Alberta.
XORTX is managed by a seasoned and experienced senior management team and governed by an independent, experienced and focused, professional Board of Directors. The Company is at a pre-phase 3 stage of development.